01 / REGULATION
Different rules, no shortcut
Ask the program to describe its operating status plainly. Do not treat a marketing claim, location, or online review as proof of legal compliance or clinical oversight.
Rosarito travel safety brief
Cross‑Border Considerations
A practical guide for U.S. and Canadian residents considering travel to Rosarito for ibogaine-based programs: what to verify before departure, what to plan for after return, and where uncertainty still matters.
01 / Start with scope
Travel does not remove the need for a care plan.
This page is for practical preparation, not medical or legal advice. A cross-border decision is not only about getting to Rosarito; it is also about screening, emergency response, and what happens once a traveler returns.
Ibogaine-based programs can involve decisions across two health systems and two regulatory environments. Before travel, it helps to review the broader Rosarito ibogaine safety overview and identify the questions that apply to an individual health history, current medicines, support network, and route home.
In the United States, ibogaine is listed as a Schedule I controlled substance under federal law, as reflected by the DEA’s drug scheduling information. Rules, enforcement, and treatment settings can differ across borders. A traveler should avoid assuming that availability in another country establishes safety, medical appropriateness, or a pathway for bringing a substance back.
Three crossings to plan for
Not a booking checklist. A way to test whether the arrangement has a credible safety structure.
02 / COVERAGE
Insurance may not follow
Unapproved treatments, complications, transport, and later follow-up may fall outside a traveler’s coverage. Confirm exclusions directly with an insurer before making plans.
03 / CONTINUITY
Return care needs a handoff
Have a local clinician or service identified in advance for medication questions, new symptoms, and follow-up after the trip rather than looking only after a concern arises.
02 / Documentation over marketing
Ask how oversight works when something changes.
Promotional language can make a program seem complete without showing how safety decisions are made. It is reasonable to ask who performs screening, what information is reviewed before acceptance, who is present during treatment, what monitoring occurs, and how an urgent transfer would be handled.
For a framework on the difference between preliminary findings and settled clinical practice, consult the site’s evidence summary for Rosarito. Ibogaine has known safety concerns, including effects relevant to heart rhythm; the FDA’s drug safety information is a useful reminder that serious medication-related risks require careful assessment rather than self-triage.
Request answers in writing where possible. Clear questions are not a sign of distrust; they are a way to see whether a program can explain its process, limits, and escalation plan without relying on reassurance alone.
03 / Process diary
Build a return plan before the outbound trip.
Local follow-up
Identify a clinician, urgent care option, or other appropriate local resource before leaving. Be prepared to share an accurate account of medicines, treatment received, symptoms, and travel dates.
Medication management
Do not make assumptions about stopping, restarting, combining, or changing prescribed medicines around travel. Bring medication questions to a qualified clinician who knows the individual history.
Emergency contacts
Share travel details with a trusted person and keep practical contacts accessible: a local support person, a return transportation plan, emergency numbers, and an insurer if coverage applies.
Transfer options
Ask what happens if the program cannot manage a complication. A credible answer identifies the escalation process, transportation arrangement, and how records would accompany a transfer.
04 / Questions to carry
Make the answers concrete.
A program’s willingness to answer specific questions can be more informative than broad claims about experience. The following prompts focus on practical details that a traveler and family can understand.
- Who conducts medical screening, and what health information or records are requested before a person is accepted?
- Who is responsible for monitoring during treatment, and what emergency equipment and written procedures are on site?
- What nearby hospital or transfer arrangement is used if a participant needs a higher level of care?
- What credentials, licenses, and roles can the program document for the people involved in clinical decisions?
- What discharge information is supplied for a local clinician after the traveler returns?
- What support, check-ins, and emergency contact plan are available after departure from Rosarito?
For background on how Coyote Measure separates safeguards from promotional claims, see the resource’s independent approach. Cross-border preparation benefits from the same standard: check what can be documented, not merely what is promised.
05 / Practical answers
A short planning FAQ
What should be arranged before travel?
Arrange a realistic plan for local follow-up, medication management, emergency contacts, transportation, and support after returning home. Ask how emergency escalation works while you are in Mexico.
Can advertising establish medical oversight?
No. Advertising is not documentation. Ask for clear answers about screening, clinician roles, monitoring, written emergency procedures, and hospital-level transfer if needed.
How can credentials be checked?
Ask what credential or license is held, where it was issued, and how it can be independently verified. For U.S. professionals, state licensing boards are generally the appropriate place to confirm an active license.
Why plan for return care?
Travel may end before questions or symptoms do. A return plan reduces the pressure to make decisions alone and gives family members a clearer route to support if concerns arise.
Documented safeguards matter more than a seamless story.
Cross-border planning should leave room for uncertainty, especially where legal status, medical oversight, insurance, and follow-up care may not align.
For Canadian travelers, government guidance on medical care outside Canada is a useful starting point for understanding why travel insurance and return-care planning deserve attention. This resource does not provide medical or legal advice.